Kinase Inhibitor [EPC]

453912 reported adverse events

Drugs of this class: SIROLIMUS EVEROLIMUS GEFITINIB SORAFENIB PALBOCICLIB ACALABRUTINIB AXITINIB LAROTRECTINIB LORLATINIB VANDETANIB ABEMACICLIB

These side effects are most commonly reported by patients taking drugs of the Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 52291
1 FATIGUE 40319
2 DIARRHOEA 36113
3 OFF LABEL USE 27137
4 NAUSEA 25758
5 RASH 16452
6 MALIGNANT NEOPLASM PROGRESSION 16081
7 ASTHENIA 16026
8 DECREASED APPETITE 15617
9 VOMITING 14831
See all common reactions for Kinase Inhibitor [EPC]

Drugs of the Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EGFR GENE MUTATION 270 0.8599
1 CYTOGENETIC ANALYSIS ABNORMAL 465 0.4942
2 NEOPLASM PROGRESSION 14357 0.4824
3 ACQUIRED GENE MUTATION 463 0.4625
4 TRANSPLANT DYSFUNCTION 503 0.3517
5 HAEMATOCRIT ABNORMAL 337 0.3297
6 TUMOUR MARKER INCREASED 1165 0.3082
7 HEPATOCELLULAR CARCINOMA 1920 0.3030
8 METASTASES TO MENINGES 499 0.3026
9 MYELOFIBROSIS 736 0.3003
See all enriched reactions for Kinase Inhibitor [EPC]